Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KD101 in Obese or Overweight Subjects
NCT02462031Phase 1Unknown
- Sponsor
- Kwang Dong Pharmaceutical Co., Ltd.
- Start
- Mar 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing KD101 with Placebo (2 arms). Primary endpoint: Maximum Plasma Concentration up to 4 weeks. Status: unknown.
02
Drugs
KD101
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02462031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462031.